Kailera Therapeutics, a clinical-stage biopharma startup making oral and injectable obesity treatments, aims to raise up to $533 million in its IPO.
The intrigue: Kailera would be the first obesity biotech to go public since the January 2025 debut of Metsera, which Pfizer bought for $10 billion last fall.
